Rani Therapeutics Holdings, Inc. — Form 8-K
Filed November 12, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On November 10, 2026, Rani Therapeutics Holdings received notice of failure to satisfy continued listing requirements, triggering Item 3.01 disclosure. The filing provides no specific details on which listing standard was violated, remediation timeline, or company response. This represents a critical corporate governance event for the $65M market-cap biotech company.
Why this rating
Delisting notice is existential threat to public company status and trading liquidity. At $65M market cap, loss of listing access could severely impair capital access and valuation.
Extracted items
Tradability signal
SHORT
conviction 49/100 · expected -1.71% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (127 in this cell) moved +2.05% in the called direction over 4 hrs; shrunk for sample size that's a +1.71% edge. Price is up 1.6% since the filing hit EDGAR — market hasn't digested it yet. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.53 ▲ 0.13% | at our read · unknown $0.52 | +10 min · unknown $0.52 ▲ 0.02% | +30 min · unknown $0.52 ▼ 1.09% | +1 hr · unknown $0.51 ▼ 2.12% | +4 hrs · unknown $0.51 ▼ 1.83% |
The stock had already moved -0.13% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.